Cue Biopharma, Inc. (CUE) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cue Biopharma (CUE) PT Lowered to $4 at Jefferies
November 15, 2024 8:59 AM ESTJefferies analyst Maury Raycroft lowered the price target on Cue Biopharma (NASDAQ: CUE) to $4.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Stock has surged ~230% following CUE's recent $12M capital raise. However, the cash overhang still remains ($32M), limiting cos ability to... More
